Validation of tissue microarray technology in ovarian cancer: Results from the nurses' health study

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 11, 2008, Pages 3043-3050

  Hecht, Jonathan L ^a   Kotsopoulos, Joanne ^b,c   Gates, Margaret A ^b,c   Hankinson, Susan E ^b,c   Tworoger, Shelley S ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; WT1 PROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; NURSE; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; TISSUE MICROARRAY; VALIDATION STUDY;

FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 55849121559     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0645     Document Type: Article

References (25)

1. Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E. Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 2001;70:255-64.
2. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005;96:671-7.
3. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 2005;5:388-96.
4. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-60.
5. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 2006;24:1823-30.
6. Armstrong B, White E, Saracci R. Principles of Exposure Measurement in Epidemiology. Oxford: Oxford University Press; 1992.
7. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
8. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
9. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004;17:790-7.
10. Gillett CE, Springall RJ, Barnes DM, Hanby AM. Multiple tissue core arrays in histopathology research: a validation study. J Pathol 2000; 192:549-53.
11. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8.
12. Hendrickson MR, Longacre TA. Classification of surface epithelial neoplasms of the ovary. Pathology (Phila) 1993;1:189-254.
13. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003;120:86-92.
14. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490-500.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
16. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
17. Layfield LJ, Saria EA, Berchuck A, et al. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. J Surg Oncol 1997;66:230-6; discussion 236-7.
18. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-24.
19. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16A-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635-40.
20. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004;23:110-8.
21. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 2002;117:944-51.
22. Vang R, Whitaker BP, Farhood AI, Silva EG, Ro JY, Deavers MT. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001;20:252-9.
23. Cameron RI, Ashe P, O'Rourke DM, Foster H, McCluggage WG. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol 2003;22:272-6.
24. Hogdall EV, Christensen L, Hogdall CK, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007;18:1051-9.
25. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006;19:97-105.